Dietary compounds as epigenetic modulating agents in cancer

Á Carlos-Reyes, JS López-González… - Frontiers in …, 2019 - frontiersin.org
Epigenetic mechanisms control gene expression during normal development and their
aberrant regulation may lead to human diseases including cancer. Natural phytochemicals …

Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer

I Gukovsky, N Li, J Todoric, A Gukovskaya, M Karin - Gastroenterology, 2013 - Elsevier
Inflammation and autophagy are cellular defense mechanisms. When these processes are
deregulated (deficient or overactivated) they produce pathologic effects, such as oxidative …

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

PK Mazur, A Herner, SS Mello, M Wirth, S Hausmann… - Nature medicine, 2015 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers and
shows resistance to any therapeutic strategy used. Here we tested small-molecule inhibitors …

Potent dual BET/HDAC inhibitors for efficient treatment of pancreatic cancer

S He, G Dong, Y Li, S Wu, W Wang… - Angewandte Chemie …, 2020 - Wiley Online Library
As one of the most aggressive and lethal human malignancies with extremely poor
prognosis, there is an urgent demand of more effective therapy for the treatment of …

UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer

Q Hu, Y Qin, S Ji, W Xu, W Liu, Q Sun, Z Zhang, M Liu… - Cancer Letters, 2019 - Elsevier
UHRF1 (ubiquitin like with plant homeodomain and ring finger domains 1) is an epigenetic
modifier that is overexpressed in some cancers, including pancreatic cancer, and mediates …

Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies

EG Chiorean, AL Coveler - Drug design, development and therapy, 2015 - Taylor & Francis
Pancreatic cancer is the fourth leading cause of cancer death in the US and is expected to
become the second leading cause of cancer-related deaths in the next decade. Despite 5 …

Interleukin-6 in inflammatory and malignant diseases of the pancreas

M Lesina, SM Wörmann, P Neuhöfer, L Song… - Seminars in …, 2014 - Elsevier
Interleukin-6 is an important pro-inflammatory cytokine strongly linked to the most burdened
exocrine pancreatic diseases including acute pancreatitis, chronic pancreatitis and …

Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer

AS Leal, CR Williams, DB Royce, PA Pioli, MB Sporn… - Cancer letters, 2017 - Elsevier
Bromodomain inhibitors (JQ1 and I-BET 762) are a new generation of selective, small
molecule inhibitors that target BET (bromodomain and extra terminal) proteins. By impairing …

Aberrant methylation patterns in cancer: a clinical view

A Videtic Paska, P Hudler - Biochemia medica, 2015 - hrcak.srce.hr
Sažetak Epigenetic mechanisms, such as DNA methylation, DNA hydroxymethylation, post-
translational modifications (PTMs) of histone proteins affecting nucleosome remodelling …

[HTML][HTML] Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects

D Neureiter, T Jäger, M Ocker… - World Journal of …, 2014 - ncbi.nlm.nih.gov
An improvement in pancreatic cancer treatment represents an urgent medical goal. Late
diagnosis and high intrinsic resistance to conventional chemotherapy has led to a dismal …